Invictus BioPharma Ltd. is an unlisted public Australian biotechnology company developing and commercialising tocotrienol products as evidence-based nutraceuticals and pharmaceuticals. 

If you wish to receive further information about the company, please contact us.

Announcements

12 February 2020

Melbourne, Victoria

Invictus BioPharma Ltd, the Company commercialising an innovative new non-invasive and direct drug and vitamin delivery platform which eliminates the use of needles, is pleased to announce that the US Patent Office has issued a Notice of Allowance for a patent for the transmucosal delivery of tocotrienols.

READ MORE

3 February 2020

Melbourne, Victoria

Invictus BioPharma Ltd, the Company commercialising an innovative new non-invasive and direct drug and vitamin delivery platform which eliminates the use of needles, says the European Patent Office has issued a Notice of Decision to Grant a patent for the transmucosal delivery of tocotrienols.

READ MORE

17 June 2019

Melbourne, Victoria

Invictus BioPharma Limited, the Company commercialising an innovative non-invasive direct drug and vitamin delivery platform, today announced the receipt of the FDA’s response to its Pre-Investigational New Drug (Pre-IND) submission.

READ MORE

28 March 2019

Melbourne, Victoria

Invictus BioPharma Limited, the Company commercialising an innovative non-invasive direct drug and vitamin delivery platform, today announced the appointment of internationally-recognised sports physiology clinical trials expert Dr Jordan Moon to its Scientific Advisory Board.

READ MORE

20 March 2019

Melbourne, Victoria

Invictus BioPharma Limited, the Company commercialising an innovative non-invasive direct drug and vitamin delivery platform, today announced the appointment of internationally respected hepatologist Professor Ed Gane as a member of its Scientific Advisory Board.

READ MORE

20 February 2019

Melbourne, Victoria

Invictus BioPharma Limited, the Company commercialising an innovative non-invasive direct drug and vitamin delivery platform, today announced the appointment of John Darling as Company Secretary.

READ MORE

12 February 2019

Melbourne, Victoria

Invictus BioPharma Ltd., the Company commercialising an innovative new non-invasive and direct drug and vitamin delivery platform, submitted a formal request on Friday, 8 February 2019, to the US Food and Drug Administration (FDA) for a pre-investigational new drug (pre-IND) consultation.

READ MORE

22 January 2019

Melbourne, Victoria

Invictus BioPharma Ltd, the Company commercialising an innovative new non-invasive and direct drug and vitamin delivery platform, says the Japanese Patent Office has issued a Notice of Allowance for the Company’s patent for the transmucosal delivery of tocotrienols.

READ MORE

22 October 2018

Melbourne, Victoria

Invictus BioPharma Ltd, the company commercialising an innovative new non-invasive and direct drug and vitamin delivery platform which avoids the use of needles, today announced the first manufacturing run of its branded nutraceutical and sports nutrition products.

READ MORE

6 August 2018

Melbourne, Victoria

Invictus Biotechnology Pty. Ltd., a private Australian biotechnology company developing and commercialising evidence-based nutraceuticals and pharmaceuticals based on a natural product (tocotrienols), today announced that it has successfully completed a proof of concept animal study on Tocotrienol ProDrug (TPDs) Delivery Platform.

READ MORE

9 July 2018

Melbourne, Victoria

Invictus Biotechnology Pty. Ltd., a private Australian biotechnology company developing and commercialising evidence-based nutraceuticals and pharmaceuticals based on a natural product (tocotrienols), today announced that it has appointed Mr Lou Panaccio as an independent Non-Executive Director and Mr Richard Estalella as an Executive Director.

READ MORE

21 May 2018

Melbourne, Victoria

Invictus Biotechnology Pty. Ltd., a private Australian biotechnology company developing and commercialising evidence-based nutraceuticals and pharmaceuticals based on a natural product (tocotrienols), today announced that it has appointed Dr Richard Pestell as a member of its Scientific Advisory Board.

READ MORE

14 May 2018

Melbourne, Victoria

Invictus Biotechnology Pty. Ltd., a private Australian biotechnology company developing and commercialising evidence-based nutraceuticals and pharmaceuticals based on a natural product (tocotrienols), today announced that it has appointed Drs Douglas Kalman and Susan Hewlings as members of its Scientific Advisory Board.

READ MORE

9 May 2018

Melbourne, Victoria

Invictus Biotechnology Pty. Ltd., a private Australian biotechnology company developing and commercialising evidence-based nutraceuticals and pharmaceuticals based on a natural product (tocotrienols), today announced that it has appointed Mr Richard Estalella as an Advisor for the Company’s launch of its nutraceutical products in the US.

READ MORE

19 March 2018

Melbourne, Victoria

Invictus Biotechnology Pty. Ltd., a private Australian biotechnology company developing and commercialising evidence-based nutraceuticals and pharmaceuticals based on a natural product (tocotrienols), today announced that it has appointed Dr David Kingston as Chair of its Scientific Advisory Board.

READ MORE

6 March 2018

Melbourne, Victoria

Invictus Biotechnology Pty. Ltd., a private Australian biotechnology company developing and commercialising evidence-based nutraceuticals and pharmaceuticals based on a natural product (tocotrienols), today announced that it has been granted the exclusive global rights to exploit a new drug delivery technology platform for tocotrienols (Tocotrienol Prodrugs) developed by the Monash Institute of Pharmaceutical Sciences (MIPS).

READ MORE

1 March 2018

Melbourne, Victoria

Invictus Biotechnology Pty. Ltd., a private Australian biotechnology company developing and commercialising evidence-based nutraceuticals and pharmaceuticals based on a natural product (tocotrienols), today announced that it has acquired the Intellectual Property Rights associated with the MELT3TM delivery platform and has been granted a new Singapore patent.

READ MORE

TOP